Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Blaise

Showing results (231-240 of 284) with videos related to

Pageof 29
Sort By:
Leukemia|December 1, 1996
Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 studyJ Reiffers, A M Stoppa, M Attal, et al.
Leukemia|April 12, 2003
Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantationC Chabannon, A-G Le Corroller, F Viret, et al.
Bone Marrow Transplantation|December 3, 2013
Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)P Chevallier, M Labopin, N Milpied, et al.
Bone Marrow Transplantation|August 16, 2016
Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysisP V O'Donnell, M Eapen, M M Horowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de MoelleM André, M Henry-Amar, J L Pico, et al.
Bone Marrow Transplantation|March 3, 2016
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamideL Castagna, S Bramanti, S Furst, et al.
Leukemia|October 1, 2010
Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie CellulaireM Mohty, M Labopin, M L Balère, et al.
Journal of Hematotherapy|December 1, 1996
Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recoveryC Faucher, A G Le Corroller, C Chabannon, et al.
Bone Marrow Transplantation|October 18, 2016
Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantationL Castagna, B Sarina, R Crocchiolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†S P Robinson, A Boumendil, H Finel, et al.
Pageof 29

Showing results (231-240 of 284) with videos related to

Sort By:
Pageof 29
Leukemia|December 1, 1996
Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 studyJ Reiffers, A M Stoppa, M Attal, et al.
Leukemia|April 12, 2003
Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantationC Chabannon, A-G Le Corroller, F Viret, et al.
Bone Marrow Transplantation|December 3, 2013
Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)P Chevallier, M Labopin, N Milpied, et al.
Bone Marrow Transplantation|August 16, 2016
Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysisP V O'Donnell, M Eapen, M M Horowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de MoelleM André, M Henry-Amar, J L Pico, et al.
Bone Marrow Transplantation|March 3, 2016
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamideL Castagna, S Bramanti, S Furst, et al.
Leukemia|October 1, 2010
Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie CellulaireM Mohty, M Labopin, M L Balère, et al.
Journal of Hematotherapy|December 1, 1996
Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recoveryC Faucher, A G Le Corroller, C Chabannon, et al.
Bone Marrow Transplantation|October 18, 2016
Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantationL Castagna, B Sarina, R Crocchiolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†S P Robinson, A Boumendil, H Finel, et al.
Pageof 29